ZIRABEV 400mg/16 ml price in UAE

Overview

Welcome to Dwaey, specifically on ZIRABEV 400mg/16 ml Concentrate for Solution for Infusion page.
This medicine contains an important and useful components, as it consists of Bevacizumab.
ZIRABEV 400mg/16 ml is available in the market in concentration 400 mg/16 ml and in the form of Concentrate for Solution for Infusion.

PFIZER EUROPE MA EEIG is the producer of ZIRABEV 400mg/16 ml and it is imported from BELGIUM, The most popular alternatives of ZIRABEV 400mg/16 ml are listed downward .

Mode Of Action

Bevacizumab binds to VEGF, the key driver of vasculogenesis and angiogenesis, and thereby inhibits the binding of VEGF to its receptors, Flt-1 (VEGFR-1) and KDR (VEGFR-2), on the surface of endothelial cells. Neutralising the biological activity of VEGF reduces the vascularisation of tumours, normalises remaining tumour vasculature and inhibits the formation of new tumour vasculature thereby inhibiting tumour growth.

Indication

Colo-rectal cancer
Lung cancers
Renal cancers
Ovarian cancers
Breast cancers and glioblastoma multiforme of the brain
Exudative ARMD

Precaution

Gastrointestinal perforations Gastrointestinal (GI) perforation, fistula formation, and/or intra-abdominal abscess unrelated to therapy duration reported in patients with colorectal cancer as well as other types of cancers Typical presentation reported as abdominal pain associated with symptoms such as constipation and vomiting Include GI perforation in the differential diagnosis of patients presenting with abdominal pain Discontinue therapy permanently in patients with GI perforation Wound healing complications Administration may result in the development of fatal wound dehiscence Discontinue therapy in patients with wound dehiscence requiring medical intervention Hemorrhage Fatal pulmonary hemorrhage can occur in patients with non-small cell lung cancer treated with chemotherapy and bevacizumab Do not administer the drug to patients with recent hemoptysis (at least 2.5 mL of red blood) Lactation: not known if excreted in breast milk; discontinuation of nursing advised during & for a prolonged period following use (due to the long half-life)

Side Effects

>10% Weakness (73-74%)
Hypertension (23-67%; grades 3/4: 8-18%)
Pain (61-62%)
Abdominal pain (50-61%; grades 3/4: 8%)
Vomiting (47-52%
grades 3/4:6-11%)
URI (40-47%)
Constipation (29-40%)
Leukopenia (grades 3/4: 37%)
Proteinuria (36%
grades 3/4: 3%)
Epistaxis (32-35%)
Ovarian failure (with mFolfox) (34%)
Diarrhea (grades 3/4: 2-34%)
Stomatitis (30-32%)
Alopecia (6-32%)
Neutropenia (grades 3/4: 6-27%)
Headache (26%; grades 3/4: 2-4%)
Dyspnea (25-26%)
Dizziness (19-26%)
GI hemorrhage (19-24%)
Dyspepsia (17-24%)
Taste alteration (14-21%)
Dry skin (7-20%)
Exfoliative dermatitis (3-19%)
Fatigue (grades 3/4: 5-19%)
Flatulence (11-19%)
Lacrimation disorder (6-18%)
Neuropathy (grades 3/4: 1-17%)
Weight loss (15-16%)
Hypokalemia (12-16%)
Skin discoloration (2-16%)
Thromboembolic events (grades 3/4: 15%)
Myalgia (8-15%)
Hypotension (7-15%)
Nausea (grades 3/4: 4-12%)
Back pain (undefined) 1-10% Dehydration (grades 3/4: 3-10%)
DVT (6-9%; grades 3/4: 9%)
Polyuria (3-6%)
Bilirubinemia (1-6%)
Colitis (1-6%)
Confusion (1-6%)
Neutropenia (5%)
Thrombocytopenia (5%)
Xerostomia (4-7%)
Ileus (grades 3/4: 4-5%)
Abnormal gait (1-5%)
Bone pain (grade 3/4: 4%)
Hyponatremia (grades 3/4: 4%)
GI perforations (<4%)
Arterial thrombosis (3-4%)
Intra-abdominal venous thrombosis (grades 3/4: 3%)
Rash desquamation (grades 3/4: 3%)
Syncope (grades 3/4: 3%)
Infusion reaction (<3%)
Cardio-cerebrovascular arterial thrombotic event (2-4%)
CHF (2%)
Wound dehiscence (1%)

Contra indication

Hypersensitivity to any component Recent hemoptysis

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Irinotecan/5–fluorouracil/leucovorin The incidence of epistaxis and grade 1 or 2 hemorrhage (including GI hemorrhage, minor gum bleeding, vaginal hemorrhage) was greater in patients receiving bevacizumab plus irinotecan/5-fluorouracil/leucovorin compared with patients receiving irinotecan/5-fluorouracil/leucovorin plus placebo. Closely monitor the patient during coadministration. Live vaccines The administration of live vaccines to patients receiving bevacizumab may result in a reduced immune response. Avoid coadministration. Paclitaxel Decreased paclitaxel exposure was seen when paclitaxel/carboplatin was given in combination with bevacizumab. Closely monitor the patient during coadministration. Sunitinib Coadministration of bevacizumab and sunitinib has been reported to cause unexpected severe toxicity (eg, microangiopathic hemolytic anemia). Coadministration of sunitinib and bevacizumab is not recommended.